Skip to main content

SB Investment Advisers (UK) Ltd's Form 4 filing

Vir Biotechnology, Inc. (VIR) · filed Oct 14, 2025

Accession no.
0001493152-25-018021
Filed
Oct 14, 2025, 4:30 PM ET
Trade date
Oct 9-10, 2025
Filing delay
5 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $1.54M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
SB Investment Advisers (UK) LtdCIK 000173150910% Owner
Softbank Vision Fund (Aiv M1) L.P.CIK 000175514310% Owner
SVF Endurance (Cayman) LtdCIK 000178233810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 9, 2025Common StockSSaleDisposed−249,060$6.14F2−$1,529,925.7715,372,309Indirect
Oct 10, 2025Common StockSSaleDisposed−2,300$6.08F4−$13,972.9615,370,009Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.9625 to $6.35. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.09. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)